文献速递眼底病与葡萄膜炎

Brolucizumab:从临床前到临床研究的演进及其对新生血管性年龄相关性黄斑变性管理的意义

Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2020-01-17

本文综述了抗VEGF药物brolucizumab(一种约26 kDa的人源化单链可变片段抗体)的临床前与临床研究进展。临床前研究显示其可穿透视网膜到达RPE/脉络膜且全身暴露极少;SEE 1/2期研究首次证实单次玻璃体腔注射在初治nAMD患者中的安全性、耐受性和疗效;OSPREY 2期研究显示其q8周方案在BCVA上与阿柏西普相当且液体消退更优;HAWK和HARRIER 3期研究显示,基于疾病活动度评估的q12周或q8周方案相比阿柏西普q8周,更少患眼出现疾病活动,且6 mg brolucizumab组分别有55.6%和51.0%的患者在负荷期后维持q12周给药至第48周。

要点

  • Brolucizumab为约26 kDa人源化单链可变片段抗体,临床前显示可穿透视网膜至RPE/脉络膜且全身暴露少。
  • HAWK和HARRIER 3期研究中,6 mg brolucizumab组分别有55.6%和51.0%患者负荷期后维持q12周至第48周。
  • OSPREY 2期研究显示brolucizumab q8周在BCVA上与阿柏西普相当,且液体消退更优。

核心结论

  • Brolucizumab的q12周方案在维持疗效和安全性的同时,可减少nAMD患者定期玻璃体腔注射的治疗负担。

研究设计与样本

  • 本文为综述,聚焦brolucizumab的开发及其临床前和临床研究,评估其疗效、耐受性和安全性。
  • 涉及SEE 1/2期研究、OSPREY 2期研究以及HAWK和HARRIER 3期研究。

主要发现

  • 临床前研究显示brolucizumab可轻易穿透视网膜到达RPE/脉络膜,且后续全身暴露极少。
  • SEE 1/2期研究首次证实单次玻璃体腔注射brolucizumab在初治nAMD患者中的安全性、耐受性和疗效。
  • OSPREY 2期研究显示brolucizumab q8周在BCVA上与阿柏西普相当,且brolucizumab实现更优的液体消退。
  • HAWK和HARRIER 3期研究中,6 mg brolucizumab组分别有55.6%和51.0%的患者在负荷期后立即维持q12周给药至第48周。
  • HAWK和HARRIER 3期研究中,相比阿柏西普q8周,更少的brolucizumab 6 mg治疗眼出现疾病活动,第16周和第48周解剖学结果示brolucizumab为强效干燥剂。

关键数值与推荐

  • Brolucizumab为约26 kDa的人源化单链可变片段(scFv)抗体,抑制VEGF-A,又称RTH258和ESBA1008。
  • HAWK和HARRIER 3期研究中,brolucizumab治疗方案(q12周或q8周)由使用功能和解剖参数(中心子区域厚度CST、视网膜内液IRF或视网膜下液SRF)进行的个体疾病活动度评估指导,对照为阿柏西普q8周。
  • OSPREY 2期研究中brolucizumab采用q8周方案,并与阿柏西普q8周进行比较。

临床怎么用

  • Brolucizumab可作为减少nAMD治疗负担的重要治疗工具,其q12周方案在维持疗效的同时减少注射频率。
  • 治疗中可根据功能和解剖参数(CST、IRF、SRF)评估个体疾病活动度,以指导q12周或q8周的给药间隔。

局限性

  • 本文为综述性文章,未报告原始研究的具体样本量、P值或置信区间等详细统计信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Improving or maintaining visual acuity is the main goal for the treatment of neovascular age-related macular degeneration (nAMD). Current nAMD standard of care dictates frequent intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) injections, which places a substantial burden on patients, caregivers, and physicians. Brolucizumab, a newly developed anti-VEGF molecule for nAMD treatment, has demonstrated longer durability and improvement in visual and anatomic outcomes in clinical studies in a q12-week regimen, indicating its potential to reduce treatment burden as an important therapeutic tool in nAMD management. This review focuses on the development of brolucizumab and the preclinical and clinical studies evaluating its efficacy, tolerability, and safety. Brolucizumab (also known as "RTH258" and "ESBA1008") is a humanized, single-chain variable fragment (scFv) antibody with a molecular mass of approximately 26 kDa that inhibits VEGF-A. Preclinical studies show that brolucizumab readily penetrates the retina to reach the retinal pigment epithelium (RPE)/choroid with minimal subsequent systemic exposure. The safety, tolerability, and efficacy of a single IVT brolucizumab administration in patients with treatment-naïve nAMD were first demonstrated in the SEE Phase 1/2 study. The OSPREY Phase 2 study showed brolucizumab to be as efficacious as aflibercept in a q8-week regimen with regard to best-corrected visual acuity (BCVA) and brolucizumab achieving greater fluid resolution. Brolucizumab-treated patients in the OSPREY study were subsequently challenged with a q12-week dosing interval, and the outcomes provided key information for the study design and end points of the Phase 3 studies. In the HAWK and HARRIER Phase 3 studies, after 3 monthly loading injections, brolucizumab treatment regimen (q12-week or q8-week) was guided by individual disease activity assessment using functional and anatomic parameters (central subfield thickness [CST], intraretinal fluid [IRF], or subretinal fluid [SRF]) versus aflibercept (q8-week). Fewer brolucizumab 6-mg treated eyes had disease activity versus aflibercept, and anatomic outcome results at weeks 16 and 48 demonstrate brolucizumab as a potent drying agent. Moreover, of patients treated with 6 mg brolucizumab, 55.6% and 51.0% maintained a q12-week dosing interval immediately after the loading phase until week 48 in HAWK and HARRIER, respectively. These Phase 3 studies demonstrated that the brolucizumab q12-week regimen maintains efficacy and safety while reducing treatment burden associated with regular IVT injections for patients with nAMD.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Nguyen QD, Das A, Do DV, et al. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020. PMID: 32107066. doi:10.1016/j.ophtha.2019.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。